文献速递儿童消化与营养儿童感染

植物乳杆菌DSM 9843(LP299V)预防儿童抗生素相关胃肠道症状的疗效与安全性:随机双盲安慰剂对照研究

Efficacy and Safety of Lactobacillus plantarum DSM 9843 (LP299V) in the Prevention of Antibiotic-Associated Gastrointestinal Symptoms in Children-Randomized, Double-Blind, Placebo-Controlled Study.
PubMed 文献 · J Pediatr · 2017-04-21

该研究为前瞻性、双盲、随机、安慰剂对照、多中心平行组研究,纳入438例1-11岁接受门诊抗生素治疗的儿童,评估LP299V减少抗生素相关稀便/水样便及胃肠道症状的效果与安全性。结果显示LP299V组与安慰剂组在稀便/水样便发生率、平均次数及抗生素相关腹泻发生率上均无显著差异,腹部症状人数亦无差异,LP299V安全性良好。

要点

  • LP299V组与安慰剂组稀便/水样便发生率分别为39%与44.5%,差异无统计学意义(P=.26)。
  • 抗生素相关腹泻发生率LP299V组2.8% vs 安慰剂组4.1%,差异无统计学意义(P=.4)。
  • LP299V在儿童中安全性良好,但未显示优于安慰剂的预防效果。

核心结论

  • 与安慰剂相比,LP299V在减少稀便/水样便发生率、平均次数及腹部症状发生率方面均未观察到有益效果。
  • LP299V在儿童中具有满意的安全性。

研究设计与样本

  • 前瞻性、双盲、随机、安慰剂对照、多中心、平行组研究,在初级医疗保健机构中纳入接受门诊抗生素治疗的儿童。
  • 共438例1-11岁儿童(男235例,女203例;平均年龄5.2±2.7岁)随机接受LP299V(N=218)或安慰剂(N=220)。
  • 儿童在抗生素治疗期间及治疗结束后1周内给予LP299V/安慰剂。
  • 主要结局指标为至少1次稀便/水样便(布里斯托粪便量表6或7型)的发生率。
  • 胃肠道症状(腹痛、腹胀、呕吐、胀气)随访至末次研究产品摄入后1周。

主要发现

  • LP299V组与安慰剂组稀便/水样便发生率相似,分别为39%与44.5%(P=.26)。
  • 两组平均稀便/水样便次数分别为3.9±3.5次与4.7±6.3次(P=.9)。
  • 抗生素相关腹泻(定义为从抗生素治疗开始后2小时至研究结束期间,每24小时≥3次稀便/水样便)发生率LP299V组为2.8%,安慰剂组为4.1%(P=.4)。
  • 两组有腹部症状的儿童人数无差异。

关键数值与推荐

  • 稀便/水样便依据布里斯托粪便量表6或7型判定。
  • 抗生素相关腹泻定义为从抗生素治疗开始后2小时至研究结束期间,每24小时≥3次稀便/水样便。
  • 研究产品在抗生素治疗期间及治疗结束后1周内给予。
  • 胃肠道症状随访至末次研究产品摄入后1周。

临床怎么用

  • 对于接受门诊抗生素治疗的1-11岁儿童,LP299V未显示可减少稀便/水样便或腹部症状,不应基于该研究结果常规推荐用于预防抗生素相关胃肠道症状。
  • LP299V在该人群中安全性良好,但需结合其他证据综合评估其使用价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if Lactobacillus plantarum DSM9843 (LP299V) reduces the frequency of antibiotic-associated loose/watery stools and gastrointestinal symptoms, and can be administered safely to children who are prescribed antibiotics. STUDY DESIGN: We performed a prospective, double-blind, randomized, placebo-controlled, multicenter, parallel-group study in children receiving outpatient antibiotic therapy in primary healthcare settings. The children were given LP299V/placebo during the antibiotic therapy and for 1 week after the end of treatment. The primary outcome measure was the incidence of at least 1 loose/watery stool (type 6 or 7 according to the Bristol Stool Form Scale). Gastrointestinal symptoms (abdominal pain, abdominal distention, vomiting, and flatulence) were followed up until 1 week after the last intake of the study product. RESULTS: A total of 438 children (male: 235, female: 203) aged 1-11 years (mean ± SD: 5.2 ± 2.7) were randomized to receive LP299V (N = 218) or placebo (N = 220). The incidence of loose/watery stools in the 2 study groups (LP299V and placebo) was similar, 39% vs 44.5% respectively (P = .26) as was the mean number of loose/watery stools (3.9 ± 3.5 vs 4.7 ± 6.3; P = .9). Antibiotic-associated diarrhea (defined as ≥3 loose/watery stools/24 hours starting from 2 hours after initiation of antibiotic treatment until the end of the study) occurred in 2.8% of the subjects receiving LP299V compared with 4.1% in the placebo arm (P = .4). The number of children with abdominal symptoms did not differ between the groups. CONCLUSIONS: No beneficial effect of LP299V compared with placebo was observed for the incidence of loose/watery stools, mean number of loose/watery stools, or the incidence of abdominal symptoms. LP299V had a satisfactory safety profile. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01940913.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Olek A, Woynarowski M, Ahrén IL, et al. Efficacy and Safety of Lactobacillus plantarum DSM 9843 (LP299V) in the Prevention of Antibiotic-Associated Gastrointestinal Symptoms in Children-Randomized, Double-Blind, Placebo-Controlled Study. J Pediatr. 2017. PMID: 28438377. doi:10.1016/j.jpeds.2017.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。